Biogen (BIIB) news

Alzheimer stocks rose in regular trading, with Eli Lilly up 3.4%, Biogen gaining 1.6% and Prothena rising 1.2%.

Alzheimer's-related stocks experienced gains in regular trading on October 14, 2026, reflecting ongoing investor interest in the sector. Eli Lilly shares rose 3.4%, Biogen increased by 1.6%, and Prothena Corporation (PRTA) added 1.2% to its value. These movements occurred amid continued research…

Bio-pharmaceutical stocks rose in intraday trading, with Biogen up 3.7%, Regeneron gaining 2.3% and Twist Bioscience rising 3.2%.

Bio-pharmaceutical stocks experienced gains during intraday trading on October 12, 2026, with several key names showing positive momentum. Biogen (BIIB) rose by 3.7%, while Regeneron (REGN) added 2.3% and Twist Bioscience (TWST) climbed 3.2%. The sector’s performance reflects ongoing investor…

BioGen shares rise as much as 5.6%, most intraday since July 29

Biogen shares rise 4.2% after JP Morgan raises to overweight from neutral

Biogen Inc. (BIIB) shares rose 4.2% on Friday following an upgrade from JP Morgan, which raised its rating on the stock to "overweight" from "neutral." The move reflects the firm's renewed confidence in Biogen's strategic direction and long-term growth potential, particularly in its neuroscience…

BIOGEN: BMO raises target price to $220 from $208

BMO Capital has raised its price target for Biogen Inc. (NASDAQ: BIIB) to $220 from $208, reflecting a positive outlook on the biotechnology company’s recent developments and strategic initiatives. The adjustment comes amid Biogen’s continued focus on neurological and neurodegenerative disease…